As per children of God for Life (9/21/23)
Two RSV (Respiratory Syncytial Virus) vaccines have been approved in 2023 – Arexvy (GSK) and Abrysvo (Pfizer). Arexvy is recommended for adults over 60 years of age and Abrysvo has also been recommended for administration to expectant mothers between 32 and 36 weeks of gestation. We have received inquiries on both and a summary of their development, pre-clinical testing and manufacture follow....
Both of the approved vaccines are ethically compromised.
No comments:
Post a Comment